{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T21:52:06Z","timestamp":1767909126343,"version":"3.49.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1603,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1111\/j.1365-2133.2010.10190.x","type":"journal-article","created":{"date-parts":[[2010,12,16]],"date-time":"2010-12-16T14:38:01Z","timestamp":1292510281000},"page":"996-1003","source":"Crossref","is-referenced-by-count":6,"title":["The direct cellular target of topically applied pimecrolimus may not be infiltrating lymphocytes"],"prefix":"10.1093","volume":"164","author":[{"given":"D.F.","family":"Fiorentino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.O.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.B.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.K.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.N.","family":"Sundram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2011,4,12]]},"reference":[{"key":"10.1111\/j.1365-2133.2010.10190.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1159\/000095289","article-title":"Discovery of topical calcineurin inhibitors and pharmacological profile of pimecrolimus","volume":"141","author":"Stuetz","year":"2006","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1111\/j.1365-2133.2010.10190.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/0167-5699(92)90111-J","article-title":"The mechanism of action of cyclosporin A and FK506","volume":"13","author":"Schreiber","year":"1992","journal-title":"Immunol Today"},{"key":"10.1111\/j.1365-2133.2010.10190.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1101\/gad.1102703","article-title":"Transcriptional regulation by calcium, calcineurin, and NFAT","volume":"17","author":"Hogan","year":"2003","journal-title":"Genes Dev"},{"key":"10.1111\/j.1365-2133.2010.10190.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nri1632","article-title":"NFAT proteins: key regulators of T-cell development and function","volume":"5","author":"Macian","year":"2005","journal-title":"Nat Rev Immunol"},{"issue":"Suppl.","key":"10.1111\/j.1365-2133.2010.10190.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/S0092-8674(02)00699-2","article-title":"NFAT signaling: choreographing the social lives of cells","volume":"109","author":"Crabtree","year":"2002","journal-title":"Cell"},{"key":"10.1111\/j.1365-2133.2010.10190.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1046\/j.1523-1747.2002.01709.x","article-title":"Localization of calcineurin\/NFAT in human skin and psoriasis and inhibition of calcineurin\/NFAT activation in human keratinocytes by cyclosporin A","volume":"118","author":"Al-Daraji","year":"2002","journal-title":"J Invest Dermatol"},{"key":"10.1111\/j.1365-2133.2010.10190.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"13921","DOI":"10.1073\/pnas.0500630102","article-title":"Bifurcated converging pathways for high Ca2+- and TGFbeta-induced inhibition of growth of normal human keratinocytes","volume":"102","author":"Sakaguchi","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/j.1365-2133.2010.10190.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.cell.2007.11.047","article-title":"NFATc1 balances quiescence and proliferation of skin stem cells","volume":"132","author":"Horsley","year":"2008","journal-title":"Cell"},{"key":"10.1111\/j.1365-2133.2010.10190.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s10735-006-9034-9","article-title":"Calcineurin inhibitors reduce nuclear localization of transcription factor NFAT in UV-irradiated keratinocytes and reduce DNA repair","volume":"37","author":"Canning","year":"2006","journal-title":"J Mol Histol"},{"key":"10.1111\/j.1365-2133.2010.10190.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1096\/fj.08-113076","article-title":"NFAT regulates induction of COX-2 and apoptosis of keratinocytes in response to ultraviolet radiation exposure","volume":"22","author":"Flockhart","year":"2008","journal-title":"FASEB J"},{"key":"10.1111\/j.1365-2133.2010.10190.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.devcel.2005.02.016","article-title":"Integration of Notch 1 and calcineurin\/NFAT signaling pathways in keratinocyte growth and differentiation control","volume":"8","author":"Mammucari","year":"2005","journal-title":"Dev Cell"},{"key":"10.1111\/j.1365-2133.2010.10190.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1111\/j.1600-0560.2009.01313.x","article-title":"A preliminary examination of the role of NFAT 3 in human skin, cultured keratocytes and dermal fibroblasts","volume":"37","author":"Al-Daraji","year":"2010","journal-title":"J Cutan Pathol"},{"key":"10.1111\/j.1365-2133.2010.10190.x-BIB13|cit13","first-page":"184","article-title":"Modulation of NFAT-5, an outlying member of the NFAT family, in human keratinocytes and skin","volume":"1","author":"Al-Daraji","year":"2009","journal-title":"Am J Transl Res"},{"key":"10.1111\/j.1365-2133.2010.10190.x-BIB14|cit14","first-page":"176","article-title":"Expression, localisation and functional activation of NFAT-2 in normal human skin, psoriasis, and cultured keratocytes","volume":"2","author":"Al-Daraji","year":"2009","journal-title":"Int J Clin Exp Med"},{"key":"10.1111\/j.1365-2133.2010.10190.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1038\/jid.2008.135","article-title":"Pimecrolimus enhances TLR2\/6-induced expression of antimicrobial peptides in keratinocytes","volume":"128","author":"Buchau","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1111\/j.1365-2133.2010.10190.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S1074-7613(00)80188-0","article-title":"Manipulating immune responses with immunosuppressive agents that target NFAT","volume":"12","author":"Kiani","year":"2000","journal-title":"Immunity"},{"key":"10.1111\/j.1365-2133.2010.10190.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1136\/bmj.38376.439653.D3","article-title":"Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials","volume":"330","author":"Ashcroft","year":"2005","journal-title":"BMJ"},{"key":"10.1111\/j.1365-2133.2010.10190.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1365-2230.2005.01709.x","article-title":"The mode of topical immunomodulators in the immunological network of atopic dermatitis","volume":"30","author":"Novak","year":"2005","journal-title":"Clin Exp Dermatol"},{"key":"10.1111\/j.1365-2133.2010.10190.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/j.1398-9995.2005.00798.x","article-title":"Inflammatory cell numbers and cytokine expression in atopic dermatitis after topical pimecrolimus treatment","volume":"60","author":"Simon","year":"2005","journal-title":"Allergy"},{"key":"10.1111\/j.1365-2133.2010.10190.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1365-2133.1994.tb08530.x","article-title":"The U.K. Working Party\u2019s Diagnostic Criteria for Atopic Dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis","volume":"131","author":"Williams","year":"1994","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2010.10190.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1034\/j.1600-0625.2001.100102.x","article-title":"The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group","volume":"10","author":"Hanifin","year":"2001","journal-title":"Exp Dermatol"},{"key":"10.1111\/j.1365-2133.2010.10190.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0140-6736(91)90134-B","article-title":"Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis","volume":"338","author":"Sowden","year":"1991","journal-title":"Lancet"},{"key":"10.1111\/j.1365-2133.2010.10190.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.0906-6705.2004.00269.x","article-title":"Pimecrolimus - an anti-inflammatory drug targeting the skin","volume":"13","author":"Grassberger","year":"2004","journal-title":"Exp Dermatol"},{"key":"10.1111\/j.1365-2133.2010.10190.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1056\/NEJMoa021481","article-title":"Endogenous antimicrobial peptides and skin infections in atopic dermatitis","volume":"347","author":"Ong","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2133.2010.10190.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s11882-006-0059-7","article-title":"Safety of topical calcineurin inhibitors in atopic dermatitis: evaluation of the evidence","volume":"6","author":"Spergel","year":"2006","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1111\/j.1365-2133.2010.10190.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.jaci.2005.02.011","article-title":"Pimecrolimus leads to an apoptosis-induced depletion of T cells but not Langerhans cells in patients with atopic dermatitis","volume":"115","author":"Hoetzenecker","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"10.1111\/j.1365-2133.2010.10190.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1038\/sj.jid.5700368","article-title":"Both pimecrolimus and corticosteroids deplete plasmacytoid dendritic cells in patients with atopic dermatitis","volume":"126","author":"Hoetzenecker","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.1111\/j.1365-2133.2010.10190.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/383837a0","article-title":"Rapid shuttling of NF-AT in discrimination of Ca2+ signals and immunosuppression","volume":"383","author":"Timmerman","year":"1996","journal-title":"Nature"},{"key":"10.1111\/j.1365-2133.2010.10190.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1600-0625.2008.00756.x","article-title":"Skin physiological parameters confirm the therapeutic efficacy of pimecrolimus cream 1% in patients with mild-to-moderate atopic dermatitis","volume":"18","author":"Aschoff","year":"2009","journal-title":"Exp Dermatol"},{"key":"10.1111\/j.1365-2133.2010.10190.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejps.2007.09.004","article-title":"Pimecrolimus: skin disposition after topical administration in minipigs in vivo and in human skin in vitro","volume":"33","author":"Gschwind","year":"2008","journal-title":"Eur J Pharm Sci"},{"key":"10.1111\/j.1365-2133.2010.10190.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1046\/j.1365-2133.1999.02974.x","article-title":"A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology","volume":"141","author":"Grassberger","year":"1999","journal-title":"Br J Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2133.2010.10190.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2133.2010.10190.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T13:51:01Z","timestamp":1676382661000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/164\/5\/996\/6642879"}},"subtitle":["Target of topical pimecrolimus"],"short-title":[],"issued":{"date-parts":[[2011,4,12]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,5]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2133.2010.10190.x","relation":{},"ISSN":["0007-0963"],"issn-type":[{"value":"0007-0963","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4,12]]}}}